ArticleVeterinary medicine and science2025
An Evaluation of Alternative Treatment Strategies in Mitigating Colistin Resistance: Targeting Plasmid Transfer Through the Use of Bambermycin or the Protein Coded by the Mcr-1 Gene With Antibodies and Streptomycin.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPlasmid mediated antimicrobial resistance continues to be a source of global concern, especially given the limited pipeline of novel antibiotics. The horizontal transfer of the plasmid mediated colistin resistance gene (mcr-1) between microorganisms confer resistance to previously susceptible bacterial strains and renders colistin and polymyxin B antimicrobials ineffective.
objectiveTo mitigate plasmid mediated colistin resistance using bambermycin and streptomycin on mcr-1 positive field strains of Escherichia coli. Furthermore, to assess if a commercial MCR-1 polyclonal antibody would have any synergistic effect on colistin in killing mcr-1 gene associated colistin-resistant E. coli in vitro.
methodsColistin-resistant E. coli strains recovered from clinical cases were subjected to checkerboard assays and conjugation assays using varying drug combinations viz colistin, bambermycin, streptomycin, MCR-1 antibody and human complement serum, to mitigate drug resistance.
resultsFollowing conjugation assay, the plasmid bound resistance gene was successfully transferred to J53 E. coli strain with colistin minimum inhibitory concentration (MIC) rising from ≤0.125 to >2 µg/mL conferring resistance to the former organism. The combination of bambermycin and colistin in a checkerboard assay proved to be synergistic in killing mcr-1 associated colistin-resistant strains. The combination of streptomycin, colistin and MCR-1 polyclonal antibody showed additive lethal effect on mcr-1 associated colistin-resistant strains. Bambermycin did not interfere with the transfer of mcr-1 bound plasmid from donors to recipient organism.
conclusionFurther studies on bambermycin's mechanism of action are required, as both inhibiting and enhancing effects have been documented. Similarly, the addition of MCR-1 polyclonal antibody in a checkerboard assay did not enhance colistin's lethal effect on mcr-1 carrying E. coli strains, thus highlighting the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.